Comparison of the Effects of Two Cholecystokinin-Receptor Antagonists, Loxiglumide and L-364,718, on the Pancreatic Secretory Response to Intraduodenal Tryptophan in Dogs

References

• Ivy A C, Oldberg E. A hormone mechanism for gallbladder contraction and evacuation. Am J Physiol 1928; 86: 599–613
   Google Scholar
• Jorpes E, Mutt V. Cholecystokinin and pancreozymin, one single hormone?. Acta Physiol Scand 1966; 66: 196–202
   PubMedGoogle Scholar
• Harper A A, Raper H S. Pancreozymin, a stimulant of the secretion of pancreatic enzymes in extracts of the small intestine. J Physiol 1943; 102: 115–25
   PubMedGoogle Scholar
• Rehfeld J F. Cholecystokinin. Clin Gastroenterol 1980; 9: 593–606
   PubMedGoogle Scholar
• Solomon T E. Biological actions of CCK in the gastrointestinal tract. Cholecystokinin antagonists in gastroenterology, G Adler, C Beglinger. Springer, Berlin 1991; 35–43
   Google Scholar
• Miller L J. Heterogenity of CCK receptors: classification and characterization. Cholecystokinin antagonists in gastroenterology, G Adler, C Beglinger. Springer, Berlin 1991; 27–34
   Google Scholar
• Jensen R T, Qian J ‐M, Lin J ‐T, Mantey S ‐A, Pisegna J ‐R, Wank S A. Distinguishing multiple CCK receptor subtypes. Studies with guinea pig chief cells and transfected human CCK receptors. Ann NY Acad Sci 1994; 713: 88–106
   PubMedGoogle Scholar
• Wank S A, Pisegna J R, De Weerth A. Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann NY Acad 1994; 713: 49–66
   PubMed Web of Science ®Google Scholar
• Silverman M A, Greenberg R E, Bank S. Cholecystokinin receptor antagonists: a review. Am J Gastroenterol 1987; 82: 703–8
   PubMed Web of Science ®Google Scholar
• Jensen R T, Gardner J D. Cholecystokinin receptor antagonists in vitro. Cholecystokinin antagonists in gastroenterology, G Adler, C Beglinger. Springer, Berlin 1991; 93–111
   Google Scholar
• Woodruff G N, Hughes J. Cholecystokinin antagonists. Annu Rev Pharmacol Toxicol 1991; 31: 469–501
   PubMed Web of Science ®Google Scholar
• Setnikar I, Bani M, Cereda R, Chisté R, Makovec F, Pacini M A, et al. Pharmacological characterization of a new potent and specific nonpolypeptidic cholecystokinin antagonist. Arzneimittelforsch 1987; 73: 703–7
   Google Scholar
• Chang R S L, Lotti V J. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci USA 1986; 83: 4923–6
   PubMed Web of Science ®Google Scholar
• Kopin A S, Lee Y ‐M, McBride E W, Miller L J, Lu M, Lin H Y, et al. Expression and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 1992; 89: 3605–9
   PubMed Web of Science ®Google Scholar
• Teyssen S, Niebergall E, Weber T, Beglinger C, Singer M V. Dose‐response effects of the CCK‐antagonist loxiglumide and the M1‐receptor antagonist telenzepine on the pancreatic protein response to intraduodenal tryptophan [abstract]. Pancreas 1993; 8: 774
   Google Scholar
• Cantor P. Effect of MK‐329 on pancreatic secretion in man. Cholecystokinin antagonists in gastroenterology, G Adler, C Beglinger. Springer, Berlin 1991; 135–42
   Google Scholar
• Hosotani R, Chowdhury P, Rayford P L. L‐364,718, a new CCK antagonist, inhibits postprandial pancreatic secretion and PP release in dogs. Dig Dis Sci 1989; 34: 462–7
   PubMedGoogle Scholar
• Niederau M, Niederau C, Strohmeyer G, Grendell J H. Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo. Am J Physiol 1989; 256: G150–7
   Google Scholar
• Singer M V, Solomon T E, Grossman M I. Pancreatic response to intestinal perfusion with tryptophan and phenylalanine [abstract]. Gastroenterology 1979; 76: 1249
   Google Scholar
• Thomas J E. An improved cannula for gastric and intestinal fistulas. Proc Soc Exp Biol Med 1941; 46: 260–1
   Google Scholar
• Singer M V, Becker S, Solomon T E, Grossman M I. Effect of adding albumin to solutions of secretin on pancreatic volume and bicarbonate response. Scand J Gastroenterol 1981; 16: 625–8
   PubMed Web of Science ®Google Scholar
• Riepl R L, Beier G, Auernhammer C J, Schopohl J, Hotz E, Petrovitsch M, . Actions of atropine and loperamide on meal‐stimulated pancreatic polypeptide and cholecystokinin release in man. Gastrointestinal tract and endocrine system, M V Singer, R Ziegler, G Rohr, et al. Kluwer, Dordrecht 1995; 476–81
   Google Scholar
• Taylor I L, Feldman M, Richardson C T, Walsh J H. Gastric and cephalic stimulation of human pancreatic polypeptide release. Gastroenterology 1978; 75: 432–7
   PubMed Web of Science ®Google Scholar
• Elashoff J D. Repeated‐measures bioassay with correlated errors and heterogenous variances: a Monte Carlo Study. Biometrics 1981; 37: 475–82
   PubMed Web of Science ®Google Scholar
• Singer M V, Niebel W, Elashoff J, Grossman M I. Does basal cholinergic activity potentiate exogenous secretin for stimulation of pancreatic bicarbonate output in dogs?. Digestion 1982; 24: 209–14
   PubMed Web of Science ®Google Scholar
• Gyr K, Beglinger C, Fried M, Grotzinger U, Kayasseh L, Stadler A G, et al. Plasma secretin and pancreatic response to various stimulants including a meal. Am J Physiol 1984; 246: G525–42
   Google Scholar
• Kim M S, Lee K Y, Chey W Y. Plasma secretin concentrations in fasting and postprandial states in dog. Am J Physiol 1979; 236: E539–44
   PubMed Web of Science ®Google Scholar
• Singer M V, Niebel W, Uhde K H, Hoffmeister D, Goebell H. Dose‐response effects of atropine on pancreatic response to secretin before and after truncal vagotomy. Am J Physiol 1985; 248: G532–38
   PubMed Web of Science ®Google Scholar
• Kerstens P J S M, Lamers C B H W, De Jong A J L, Hessels M, Hefkenscheid J CM. Physiological plasma concentrations of cholecystokinin stimulate pancreatic enzyme secretion and gallbladder concentration in man. Life Sci 1985; 36: 565–9
   PubMed Web of Science ®Google Scholar
• Gabryelewicz A, Kulesza E, Konturek S J. Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal‐stimulated pancreatic secretion in man. Scand J Gastroenterol 1990; 25: 731–8
   PubMed Web of Science ®Google Scholar
• Jansen J B M J, Jebbink M C, Lamers C B H W. Effect of loxiglumide (CR‐1505) on bombesin‐ and meal‐stimulated plasma cholecystokinin in man. Eur J Clin Pharmacol 1990; 38: 367–70
   PubMedGoogle Scholar
• Schmidt W E, Creutzfeld W, Schleser A, Choudhury A R, Nustede R, Höcker M, et al. Role of CCK in regulation of pancreaticbiliary functions and GI motility in humans: effect of loxiglumide. Am J Physiol 1991; 260: G197–206
   PubMedGoogle Scholar
• Thor P, Laskiewicz J, Konturek P, Konturek S J. Cholecystokinin in the regulation of intestinal motility and pancreatic secretion in dogs. Am J Physiol 1988; 255: G489–504
   Google Scholar
• Schmidt W E, Creutzfeldt W, Schleser A, Choudhury A R, Nustede R, Höcker M, et al. Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide. Am J Physiol 1991; 260: G197–206
   PubMedGoogle Scholar
• Hildebrand P, Beglinger C, Köhler E, Setnikar I, Gyr K. Biological effects of a proglumide derivative as cholecystokinin antagonist in conscious dogs. Regul Pept 1987; 18: 213–20
   PubMedGoogle Scholar
• Setnikar I, Chisté R, Makovec F, Rovati L C, Warrington S J. Pharmakokinetics of loxiglumide after single intravenous or oral doses in man. Arzneimittelforsch 1988; 38: 716–20
   PubMed Web of Science ®Google Scholar
• Berlin R G, Freidinger R M. Characterization of MK‐329. Cholecystokinin antagonists in gastroenterology, G Adler, C Beglinger. Springer, Berlin 1991; 70–9
   Google Scholar
• Teyssen S, Niebergall E, Wetzel D, Beglinger C, Singer M V. Comparison of the action of the CCK‐receptor antagonists loxiglumide and L‐364,718 and of the action of the M1‐receptor antagonist telenzepine on the pancreatic protein response to intestinal tryptophan [abstract]. Gastroenterology 1995; 108: A396
   Google Scholar
• Lotti V J, Lotti R S L. A new potent and selective nonpeptide gastrin antagonist and brain cholecystokinin receptor (CCK‐B) ligand: L‐365,260. Eur J Pharmacol 1989; 162: 273–80
   PubMed Web of Science ®Google Scholar
• Zhou W, Povoski S P, Rosen N A, Longnecker D S, Bell R H, Jr. Characterization of cholecystokinin receptors in rat pancreas. Ann NY Acad Sci 1994; 713: 331–3
   PubMedGoogle Scholar
• Fourmy D, Zahidi A, Fabre R, Guidet M, Pradayrol L, Ribet A. Receptors for cholecystokinin and gastrin peptides display specific binding properties and are structurally different in guinea‐pig and dog pancreas. Eur J Biochem 1987; 165: 683–92
   PubMedGoogle Scholar
• Millington W R, Mueller G P, Lavigne G L. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin‐stimulated β‐endorphin secretion from the rat pituitary. J Pharm Exp Ther 1992; 261: 454–61
   PubMedGoogle Scholar
• Schmidt W E. Cholecystokinin is a negative regulator of gastric acid secretion and gastrin release in humans: role of somatostatin. Gastrointestinal tract and endocrine system, M V Singer, R Ziegler, G Rohr. Kluwer, Dordrecht 1995; 146–52
   Google Scholar
• Grendell J H. Experimental pancreatitis. Cholecystokinin antagonists in gastroenterology, G Adler, C Beglinger. Springer, Berlin 1991; 197–202
   Google Scholar
• Lamers C B H W, Douglas B R, Jansen J M B J, Woutersen R A. Cholecystokinin‐receptor antagonists in experimental pancreatic tumor growth. Cholecystokinin antagonists in gastroenterology, G Adler, C Beglinger. Springer, Berlin 1991; 203–8
   Google Scholar